Why "disruptive" has no space in healthcare
The 'disruption' playbook is killing your Go-to-Market strategy
The term "disruptive," borrowed from Silicon Valley, fundamentally clashes with the reality of healthcare. While the wider tech industry champions "moving fast and breaking things" to outpace competitors, applying this ethos to MedTech and HealthTech is a fast track to procurement gridlock, stalled revenue, and burned capital.
Founders and investors often wonder why a brilliant clinical innovation is hitting institutional friction. More often than not, it’s because they are trying to disrupt a system that requires alignment.
Here is why the concept of disruption is a mismatch for healthcare commercialisation and what it takes to actually scale.
"Move Fast and Break Things" Doesn't Survive Procurement
The ultimate currency in consumer technology is user engagement. The ultimate currency in healthcare is human life and systemic efficiency. Disruptive innovation relies on launching minimum viable products (MVPs), testing them on live users, and fixing bugs iteratively.
In healthcare, regulations like HIPAA, GDPR, and FDA/CE approval pathways are not mere friction to be optimised away. Regulatory approvals are the baseline requirements for entry. When MedTech or HealthTech companies treat medical diagnostics or care pathways like consumer software products, they fail the very first rigorous market viability assessment by hospital buyers and payers.
The Danger of Ecosystem Fragmentation
Healthcare is not a linear supply chain that can be easily disintermediated. It is a highly complex, interconnected web of providers, payers, regulators, and patients.
The Ripple Effect: If a startup tries to "disrupt" one narrow vertical by bypassing the primary care provider or existing Electronic Health Records (EHR), they create data silos.
The Buyer's Veto: Clinical decision-makers will not adopt a fragmented solution that increases their cognitive load. If your product forces doctors to piece together incomplete medical histories, your value proposition will not land, and your GTM strategy will stall.
The Human Trust Factor
Disruption often seeks to replace human labor with automation to achieve immediate scale. While AI and workflow automation are critical tools, attempting to substitute human care entirely with unproven algorithms alienates patients and degrades the quality of care. Healthcare buyers know how to evaluate risk, and they rarely allocate budget to solutions that break the therapeutic alliance between patient and clinician.
From Disruption to System-Aligned Growth
Ultimately, healthcare buyers do not want disruption.
Winning patients, payers, and investors requires an approach that integrates seamlessly into existing clinical workflows and solves real-world health system priorities. To turn an early-stage innovation into a scalable, fundable business, leaders must replace reactive disruption with clear pathways to access and adoption.
At Buoyancy Health Strategy, we help MedTech and HealthTech leaders bridge the gap between innovation and adoption. If you are hitting institutional friction or looking to build a go-to-market plan that clinical decision-makers actually say yes to, get in touch today.
Buoyancy Health Strategy
Steady. Strategic. Scalable Healthcare Growth
© 2026 Buoyancy Health Strategy Ltd. All rights reserved.